ReviewTranslational gastroenterology and hepatology2026
Gelatin tannate in pediatric infectious gastroenteritis.
Review in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute gastroenteritis (AGE) causes impairment of the gastrointestinal mucus and epithelium. Adjuvant treatment to oral rehydration is recommended to shorten the duration of diarrhea. The objective of this review was to review and discuss the available evidence of gelatin tannate in the management of AGE in pediatrics. Data from MEDLINE, Embase, CINAHL, Cochrane Central Register of Controlled Trials, LILACS and grey literature were analyzed. Several trials performed in Turkey, Italy and Romania in overall 782 children showed that gelatin tannate decreased the duration of the diarrhea with a beneficial efficacy on stool consistency demonstrated already 12 hours after the start of its administration. Differences in favor of gelatin tannate were already apparent after 12 hours of administration. All trials showed beneficial outcomes, except the Polish study (72 children) which showed no difference between gelatin tannate and placebo in duration of diarrhea. In another trial testing a different tannate, diarrhea lasted for 2.0±0.27 days in the intervention group versus 3.75±0.30 days in the placebo group (P<0.001). The administration of gelatin tannate in combination with oral rehydration solution (ORS) was shown to be effective and of rapid onset in children presenting infectious AGE, showing a shortening of the diarrhea within ±24 hours. It would be of particular interest to test gelatin tannate in developing countries, since most data come from Eastern Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.